Popular
BlogNEW
CompaniesNEW
Finance
Technology
Banking
Information Technology
Oil and Energy
Internet
Mining and Metals
Communications
Real Estate
Biotechnology
Automotive
Medical
Retail
Energy
Q3 2023 Results slide image

Q3 2023 Results

Company overview Financial review Conclusions Appendix References Novartis Capital Markets Day, focus R&D November 28, 2023 London Key R&D assets will include: Kisqali®, Pluvicto®, Scemblix®, iptacopan, remibrutinib Additionally, a short update on strategy 30 Investor Relations | Q3 2023 Results 1 NOVARTIS | Reimagining Medicine
View entire presentation

Product

HomeSearchAccount

Categories

Finance PresentationsTechnology PresentationsBanking PresentationsInformation Technology PresentationsOil and Energy PresentationsInternet PresentationsMining and Metals PresentationsCommunications PresentationsReal Estate PresentationsBiotechnology PresentationsAutomotive PresentationsMedical PresentationsRetail PresentationsEnergy Presentations

Company

InsightsContactSupport

Legal

Terms of ServicePrivacy Policy

Connect

TwitterLinkedInInstagramYouTube